Target ACE2, Spike protein
ACE2; any specific functions of spike protein; see also RSP - On RAS drugs
| 32449939 2020. SARS-CoV-2 spike glycoprotein-binding proteins expressed by upper respiratory tract bacteria may prevent severe viral infection. |
regulation of ace2
32291076 ä. EZH2-mediated H3K27me3 inhibits ACE2 expression
32133153 2020. Comparative genetic analysis of the novel coronavirus (2019-nCoV/SARS-CoV-2) receptor ACE2 in different populations
32372801 2020. (ACE2) Does a cell protein explain covid-19 severity?
32302706 2020. Physiological and pathological regulation of ACE2, the SARS-CoV-2 receptor
| 32333398 2020. A hypothesis for pathobiology and treatment of COVID-19: The centrality of ACE1/ACE2 imbalance |
32442315 2020. Alternative splicing of ACE2 possibly generates variants that may limit the entry of SARS-CoV-2: a potential therapeutic approach using SSOs.
ace2 species specificity clade specificity
32092392 2020. Analysis of angiotensin-converting enzyme 2 (ACE2) from different species sheds some light on cross-species receptor usage of a novel coronavirus 2019-nCoV
32199943 ä. Predicting the angiotensin converting enzyme 2 (ACE2) utilizing capability as the receptor of SARS-CoV-2
32100877 ä. Composition and divergence of coronavirus spike proteins and host ACE2 receptors predict potential intermediate hosts of SARS?CoV?2
32249956 ä. Structural variations in human ACE2 may influence its binding with SARS?CoV?2 spike protein
32374452 2020. SARS-CoV-2: Structural diversity, phylogeny, and potential animal host identification of spike glycoprotein
32239522 ä. SARS?CoV?2 spike protein favors ACE2 from Bovidae and Cricetidae
32520981 2020. ACE2 diversity in placental mammals reveals the evolutionary strategy of SARS-CoV-2.
any receptors in target tissues
32199615 ä. Single cell RNA sequencing of 13 human tissues identify cell types and receptors of human coronaviruses
ACE2 expression in target tissues
32430651 2020. The SARS-CoV-2 receptor, ACE-2, is expressed on many different cell types: implications for ACE-inhibitor- and angiotensin II receptor blocker-based cardiovascular therapies.
32490715 2020. In vitro analysis of the renin-angiotensin system and inflammatory gene transcripts in human bronchial epithelial cells after infection with severe acute respiratory syndrome coronavirus.
32279908 ä. Is the ACE2 Overexpression a Risk Factor for COVID-19 Infection?
32251718 2020. ACE2 at the centre of COVID-19 from paucisymptomatic infections to severe pneumonia
32227090 ä. The ACE2 expression in human heart indicates new potential mechanism of heart injury among patients infected with SARS-CoV-2
32364961 2020. Severe respiratory SARS-CoV2 infection: Does ACE2 receptor matter?
32448590 ä. Marked Up-Regulation of ACE2 in Hearts of Patients With Obstructive Hypertrophic Cardiomyopathy: Implications for SARS-CoV-2 Mediated COVID-19
32422146 2020. Type 2 inflammation modulates ACE2 and TMPRSS2 in airway epithelial cells.
32531372 2020. Expression of SARS-CoV-2 Receptor ACE2 and Coincident Host Response Signature Varies by Asthma Inflammatory Phenotype.
32366279 2020. Genetic alteration, RNA expression, and DNA methylation profiling of coronavirus disease 2019 (COVID-19) receptor ACE2 in malignancies: a pan-cancer analysis.
32442454 2020. Which cancer type has the highest risk of COVID-19 infection?
32454066 2020. High expression of ACE2 on the keratinocytes reveals skin as a potential target for SARS-CoV-2.
32413354 2020. Age, inflammation and disease location are critical determinants of intestinal expression of SARS-CoV-2 receptor ACE2 and TMPRSS2 in inflammatory bowel disease.
32339157 2020. ACE2 correlated with immune infiltration serves as a prognostic biomarker in endometrial carcinoma and renal papillary cell carcinoma: implication for COVID-19.
32395525 2020. A profiling analysis on the receptor ACE2 expression reveals the potential risk of different type of cancers vulnerable to SARS-CoV-2 infection.
| 32413319 2020. SARS-CoV-2 Receptor ACE2 Is an Interferon-Stimulated Gene in Human Airway Epithelial Cells and Is Detected in Specific Cell Subsets across Tissues. |
32499922 2020. ACE2 expression and sex disparity in COVID-19.
32525565 2020. Elevated expression of ACE2 in tumor-adjacent normal tissues of cancer patients.
32526012 2020. ACE2 Expression is Increased in the Lungs of Patients with Comorbidities Associated with Severe COVID-19.
ace2 amplification
32469114 2020. An update on ACE2 amplification and its therapeutic potential.
soluble ace2
32391299 2020. COVID-19 Infection and Circulating ACE2 Levels: Protective Role in Women and Children.
32410690 2020. Age and sex differences in soluble ACE2 may give insights for COVID-19.
32396773 2020. Truncated human angiotensin converting enzyme 2; a potential inhibitor of SARS-CoV-2 spike glycoprotein and potent COVID-19 therapeutic agent.
32333836 ä. Inhibition of SARS-CoV-2 Infections in Engineered Human Tissues Using Clinical-Grade Soluble Human ACE2
32398309 2020. Could the smoking gun in the fight against Covid-19 be the (rh) ACE2?
32438383 2020. Inhaled modified angiotensin converting enzyme 2 (ACE2) as a decoy to mitigate SARS-CoV-2 infection.
Structure spike/ace2
| 32500793 2020. Repurposing Nimesulide, a Potent Inhibitor of the B0AT1 Subunit of the SARS-CoV-2 Receptor, as a Therapeutic Adjuvant of COVID-19. |
| 32492195 2020. Functional prediction and frequency of coding variants in human ACE2 at binding sites with SARS-CoV-2 spike protein on different populations. |
32448098 2020. Structural and simulation analysis of hotspot residues interactions of SARS-CoV 2 with human ACE2 receptor.
32401043 2020. Conserved High Free Energy Sites in Human Coronavirus Spike Glycoprotein Backbones.
| 32404529 2020. Comparison of SARS-CoV-2 spike protein binding to ACE2 receptors from human, pets, farm animals, and putative intermediate hosts. |
32478523 2020. Comparing the Binding Interactions in the Receptor Binding Domains of SARS-CoV-2 and SARS-CoV.
32422996 2020. Highly Conserved Homotrimer Cavity Formed by the SARS-CoV-2 Spike Glycoprotein: A Novel Binding Site.
32057769 2020. The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade
32512386 2020. Proteolytic Cleavage of the SARS-CoV-2 Spike Protein and the Role of the Novel S1/S2 Site.
32503918 2020. Enhanced receptor binding of SARS-CoV-2 through networks of hydrogen-bonding and hydrophobic interactions.
32155444 ä. Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein
32178593 2020. Emerging WuHan (COVID-19) coronavirus: glycan shield and structure prediction of spike glycoprotein and its interaction with human CD26
32320687 ä. Phylogenetic Analysis and Structural Modeling of SARS-CoV-2 Spike Protein Reveals an Evolutionary Distinct and Proteolytically Sensitive Activation Loop
32009228 2020. Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission
32075877 2020. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
32081428 2020. Structure analysis of the receptor binding of 2019-nCoV
32142651 2020. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor
32203189 ä. Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine
32275855 ä. Structural and Functional Basis of SARS-CoV-2 Entry by Using Human ACE2
32201080 ä. Spike protein recognition of mammalian ACE2 predicts the host range and an optimized ACE2 for SARS-CoV-2 infection
32210742 2020. Role of changes in SARS-CoV-2 spike protein in the interaction with the human ACE2 receptor: An in silico analysis
32327200 ä. Covid-19 and the angiotensin-converting enzyme (ACE2): Areas for research
| 32274964 2020. A review on the cleavage priming of the spike protein on coronavirus by angiotensin-converting enzyme-2 and furin |
31996437 2020. Receptor Recognition by the Novel Coronavirus from Wuhan: an Analysis Based on Decade-Long Structural Studies of SARS Coronavirus
| 32362314 ä. A Multibasic Cleavage Site in the Spike Protein of SARS-CoV-2 Is Essential for Infection of Human Lung Cells |
32221306 2020. Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV
| 32150576 2020. Structure of mouse coronavirus spike protein complexed with receptor reveals mechanism for viral entry |
32245784 2020. A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV
| 32366695 ä. Site-specific glycan analysis of the SARS-CoV-2 spike |
32132184 2020. Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2
32198713 ä. A Unique Protease Cleavage Site Predicted in the Spike Protein of the Novel Pneumonia Coronavirus (2019-nCoV) Potentially Related to Viral Transmissibility
32365751 2020. The SARS-CoV-2 Exerts a Distinctive Strategy for Interacting with the ACE2 Human Receptor
32378705 2020. A virus that has gone viral: amino acid mutation in S protein of Indian isolate of Coronavirus COVID-19 might impact receptor binding, and thus, infectivity
32132669 2020. Novel antibody epitopes dominate the antigenicity of spike glycoprotein in SARS-CoV-2 compared to SARS-CoV
32338224 2020. Focus on Receptors for Coronaviruses with Special Reference to Angiotensin-converting Enzyme 2 as a Potential Drug Target - A Perspective
32363391 ä. Deducing the N- and O- glycosylation profile of the spike protein of novel coronavirus SARS-CoV-2
| 32374903 2020. SARS-CoV-2 viral spike G614 mutation exhibits higher case fatality rate |
32376714 2020. Gene of the month: the 2019-nCoV/SARS-CoV-2 novel coronavirus spike protein
32225176 2020. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor
32225175 2020. Structural basis of receptor recognition by SARS-CoV-2
32329276 2020. Spike protein in the detection and treatment of novel coronavirus
C7190498 ä. The biological characteristics of SARS-CoV-2 spike protein Pro330-Leu650
32125455 ä. Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target
32369402 2020. ANNALS EXPRESS: Coronavirus disease 2019 (COVID-19) and the renin-angiotensin system: a closer look at angiotensin-converting enzyme 2 (ACE2)
32354022 2020. ACE2: The key Molecule for Understanding the Pathophysiology of Severe and Critical Conditions of COVID-19: Demon or Angel?
32306452 2020. Angiotensin-converting enzyme 2 in severe acute respiratory syndrome coronavirus and SARS-CoV-2: A double-edged sword?
32464271 2020. Could the D614G substitution in the SARS-CoV-2 spike (S) protein be associated with higher COVID-19 mortality?
32383269 2020. In silico studies on the comparative characterization of the interactions of SARS-CoV-2 spike glycoprotein with ACE-2 receptor homologs and human TLRs.
32463239 2020. Is the Rigidity of SARS-CoV-2 Spike Receptor-Binding Motif the Hallmark for Its Enhanced Infectivity? Insights from All-Atom Simulations.
32502733 2020. Exploring the genomic and proteomic variations of SARS-CoV-2 spike glycoprotein: A computational biology approach.
32410735 2020. Interaction of the spike protein RBD from SARS-CoV-2 with ACE2: Similarity with SARS-CoV, hot-spot analysis and effect of the receptor polymorphism.
32415260 2020. Key residues of the receptor binding motif in the spike protein of SARS-CoV-2 that interact with ACE2 and neutralizing antibodies.
32518941 2020. Identification of 22 N-glycosites on spike glycoprotein of SARS-CoV-2 and accessible surface glycopeptide motifs: implications for vaccination and antibody therapeutics.
Drug design
| 32437749 2020. Human Intestinal Defensin 5 Inhibits SARS-CoV-2 Invasion by Cloaking ACE2. |
| C7151553 2020. COVID-19 Coronavirus spike protein analysis for synthetic vaccines, a peptidomimetic antagonist, and therapeutic drugs, and analysis of a proposed achilles? heel conserved region to minimize probability of escape mutations and drug resistance |
32286790 ä. Computational Design of ACE2-Based Peptide Inhibitors of SARS-CoV-2
32455942 2020. Potential Therapeutic Targeting of Coronavirus Spike Glycoprotein Priming.
32527713 2020. In Silico computational screening of Kabasura Kudineer - Official Siddha Formulation and JACOM against SARS-CoV-2 spike protein.
32231345 2020. Inhibition of SARS-CoV-2 infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion
32354636 ä. Blockade of SARS-CoV-2 infection by recombinant soluble ACE2
32332922 ä. SARS-CoV-2 infection of kidney organoids prevented with soluble human ACE2
32294562 ä. A search for medications to treat COVID-19 via in silico molecular docking models of the SARS-CoV-2 spike glycoprotein and 3CL protease
32359080 2020. Off-target ACE2 ligands: Possible therapeutic option for CoVid-19?
32167153 2020. Soluble angiotensin-converting enzyme 2: a potential approach for coronavirus infection therapy?
32373991 2020. In silico screening of natural compounds against COVID-19 by targeting Mpro and ACE2 using molecular docking
32232976 2020. CD-sACE2 inclusion compounds: An effective treatment for coronavirus disease 2019 (COVID-19)
32362217 2020. In silico study the inhibition of angiotensin converting enzyme 2 receptor of COVID-19 by Ammoides verticillata components harvested from Western Algeria
32345124 2020. An in-silico evaluation of different Saikosaponins for their potency against SARS-CoV-2 using NSP15 and fusion spike glycoprotein as targets
32379346 2020. ACE2 Activators for the Treatment of Covid 19 Patients
32332765 2020. Neutralization of SARS-CoV-2 spike pseudotyped virus by recombinant ACE2-Ig
32376627 2020. Design of potent membrane fusion inhibitors against SARS-CoV-2, an emerging coronavirus with high fusogenic activity
32380200 ä. In Silico Design of Antiviral Peptides Targeting the Spike Protein of SARS-CoV-2
| C7197610 ä. Isolation of a human monoclonal antibody specific for the receptor binding domain of SARS-CoV-2 using a competitive phage biopanning strategy |
| 32231345 ä. Inhibition of SARS-CoV-2 infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion |
32336762 2012. Design of Angiotensin?converting Enzyme 2 (ACE2) Inhibitors by Virtual Lead Optimization and Screening
32380200 2020. In silico design of antiviral peptides targeting the spike protein of SARS-CoV-2
32065055 2020. Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody
32285293 ä. Searching therapeutic strategy of new coronavirus pneumonia from angiotensin-converting enzyme 2: the target of COVID-19 and SARS-CoV
32313207 ä. Human monoclonal antibodies block the binding of SARS-CoV-2 spike protein to angiotensin converting enzyme 2 receptor
32451080 ä. A possible strategy to fight COVID-19: Interfering with spike glycoprotein trimerization
32423095 2020. The Expression and Polymorphism of Entry Machinery for COVID-19 in Human: Juxtaposing Population Groups, Gender, and Different Tissues.
32403995 2020. Development of multi-specific humanized llama antibodies blocking SARS-CoV-2/ACE2 interaction with high affinity and avidity.
32592145 2020. Identification of a Potential Peptide Inhibitor of SARS-CoV-2 Targeting its Entry into the Host Cells.
32551560 2020. Discovery of Aptamers Targeting Receptor-Binding Domain of the SARS-CoV-2 Spike Glycoprotein.
32547694 2020. Blocking Coronavirus 19 Infection via the SARS-CoV-2 Spike Protein: Initial Steps.
32593613 2020. Testing of natural products in clinical trials targeting the SARS-CoV-2 (Covid-19) Viral Spike Protein-Angiotensin Converting Enzyme-2 (ACE2) interaction.
32540428 2020. Eltrombopag is a potential target for drug intervention in SARS-CoV-2 spike protein.
32552462 2020. Identification of bioactive compounds from Glycyrrhiza glabra as possible inhibitor of SARS-CoV-2 spike glycoprotein and non-structural protein-15: a pharmacoinformatics study.
| 32565126 2020. Targeting the SARS-CoV-2 spike glycoprotein prefusion conformation: virtual screening and molecular dynamics simulations applied to the identification of potential fusion inhibitors. |
